Delving into the Latest Updates on Iocetamic Acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Iocetamic acid (USAN), Cholebrine

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Contrast agents

Originator Organization

Mallinckrodt Plc

Active Organization-

Inactive Organization

Mallinckrodt Medical, Inc.

Drug Highest PhaseWithdrawn

First Approval Date

US (16 May 1973),

Contrast agents

Regulation-

Login to view timeline

Structure

Molecular FormulaC12H13I3N2O3

InChIKeyGSVQIUGOUKJHRC-UHFFFAOYSA-N

CAS Registry16034-77-8

AbstractWe report the first case of severe thrombocytopenia occurring after ingestion of a widely used cholecystographic medium, iocetamic acid. The patient had not been given any treatment before he received the gallbladder contrast medium. Onset of symptoms was acute, and the clinical course was benign with complete recovery after one week. Bone marrow aspiration showed increased numbers of megakaryocytes, suggesting that platelets were rapidly removed from circulation. In vitro tests for antiplatelet antibodies were not performed because iocetamic acid is insoluble in aqueous solutions. Since only a few cases of thrombocytopenia following ingestion of iodine‐compounds have been reported, it seems highly unlikely that purpura will be, in the future, a major hazard in cholecystography. However, it would be wise to question patients as to any prior sensitivity to iodine before proceeding with oral cholecystography.

100 Deals associated with Iocetamic Acid

Login to view more data